Literature DB >> 54680

First-line chemotherapy in the retreatment of bacteriological relapses of pulmonary tuberculosis following a shortcourse regimen.

.   

Abstract

Totals of 404 Chinese and 778 East African patients with newly diagnosed drug-sensitive pulmonary tuberculosis were treated with short-course regiments of antituberculosis chemotherapy. The Chinese received 6-month and 9-month regimens of streptomycin plus isoniazid plus pyrazinamide, and the East Africans 6-month regiments of streptomycin plus isoniazid alone or with a third drug. 28 Chinese and 45 African patients who relapsed with drug-sensitive strains after their short-course regimen were retreated with standard first-line chemotherapy. The Chinese were given every single dose under full supervision, but the Africans the initial phase only. At 12 months from the start of their retreatment, all 28 Chinese and 40 (89%) of the 45 Africans had a favourable therapeutic response on their retreatment regimen. 2 of the 5 East African patients whose retreatment failed were known to have been irregular in taking their drugs.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 54680

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  3 in total

1.  Quadoctomycin, a 48-membered macrolide antibiotic from Streptomyces sp. MM168-141F8.

Authors:  Ryuichi Sawa; Yumiko Kubota; Maya Umekita; Masaki Hatano; Chigusa Hayashi; Masayuki Igarashi
Journal:  J Antibiot (Tokyo)       Date:  2017-11-15       Impact factor: 2.649

2.  Detection of mRNA transcripts and active transcription in persistent Mycobacterium tuberculosis induced by exposure to rifampin or pyrazinamide.

Authors:  Y Hu; J A Mangan; J Dhillon; K M Sole; D A Mitchison; P D Butcher; A R Coates
Journal:  J Bacteriol       Date:  2000-11       Impact factor: 3.490

Review 3.  The chemotherapy of tuberculosis: past, present and future.

Authors:  D Mitchison; G Davies
Journal:  Int J Tuberc Lung Dis       Date:  2012-06       Impact factor: 2.373

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.